Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YD0293
- Development stage
- Phase 1
- Lead developer
- Shanghai Yidian Pharmaceutical Technology Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YD0293 is an investigational small molecule drug developed by Shanghai Yidian Pharmaceutical Technology Development. It is currently in Phase 1 clinical trials in China. The primary objective of the ongoing studies is to evaluate the safety and tolerability of single and multiple oral doses of YD0293 tablets in healthy subjects. Secondary objectives include assessment of pharmacokinetics (PK), food effects on PK, impact on QT/QTc interval, and changes in neutrophil elastase (NE) concentration after repeated dosing. The main indication under investigation for YD0293 is bronchiectasis[1][3].
- Other names
- YD0293YD-0293YD 0293
Beyond the preview
Go deeper on YD0293.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YD0293.